![]() ![]() More specifically, they found that inosine was able to downregulate the inflammation-promoting interleukin (IL)-6, upregulate the anti-inflammatory IL-10, and improve acute inflammatory lung injury caused by multiple infectious agents. Using a mouse model, the researchers demonstrated the therapeutic effects of the broad-spectrum anti-inflammatory agent inosine. While attempting to develop effective treatment modalities for COVID-19, the researchers made a remarkable discovery. Glucocorticoid and anti-cytokine therapies are frequently administered to treat COVID-19 but have limited clinical efficacy in severe and critical cases.” The corresponding author, Yue Gao, from the Beijing Institute of Radiation Medicine and Tianjin University of Traditional Chinese Medicine says, “Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced cytokine storms constitute the primary cause of coronavirus disease 19 (COVID-19) progression, severity, criticality, and death. These findings were made available online on 22 October 2022 and subsequently published in Volume 13, Issue 1 of Journal of Pharmaceutical Analysis ( JPA) on 1st January 2023. A recent example includes the discovery of the broad-spectrum anti-inflammatory effects of inosine, a nucleoside found in transfer RNAs, by researchers in China. Knowing various pathophysiological mechanisms dramatically expedites the process of drug discovery. As the search for high-quality pharmaceutical drugs continues, researchers also continue spending countless hours discovering the underlying mechanisms of drug action. ![]()
0 Comments
Leave a Reply. |